Pain, headache, and migraine is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 50.0 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Pain and headache. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
Neurotropic B vitamins play crucial roles as coenzymes and beyond in the nervous system, but they can improve certain neurological conditions even without a (proven) deficiency.
It is shown that in preclinical models, reduced thiamine can drive AD‐like abnormalities, including memory deficits, neuritic plaques, and hyperphosphorylation of tau, and excessThiamine diminishesAD‐like pathologies.
Current knowledge of the biological functions of thiamine, its antioxidant properties, and the effects of its deficiency in the body are presented.
The results suggest a lower intake of calcium, vitamin D and dairy and a higher intake of fruit, vegetables, protein, phosphorus, selenium, thiamine, riboflavin and vitamin B12 than recommended.
The results demonstrate that the D. melanogaster microbiota functions to provision thiamine to its host in a low-thiamine environment, enough to allow the development of flies on aThiamine-free diet.
A literature review of the current knowledge of the disease including related clinical phenotypes, treatment approaches, update of pathogenic variants, as well as in vitro and in vivo functional models that provide pathogenic evidence and propose mechanisms fo